Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) EPS (Weighted Average and Diluted) (2016 - 2025)

Immucell's EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$0.32 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 500.0% year-over-year to -$0.32; the TTM value through Dec 2025 reached -$0.12, up 55.56%, while the annual FY2025 figure was -$0.12, 53.85% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.32 in Q4 2025 per ICCC's latest filing, down from -$0.02 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.16 in Q1 2025 to a low of -$0.32 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.07, with a median of -$0.07 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 2200.0% in 2022, then surged 366.67% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.01 in 2021, then tumbled by 2200.0% to -$0.21 in 2022, then rose by 28.57% to -$0.15 in 2023, then skyrocketed by 153.33% to $0.08 in 2024, then plummeted by 500.0% to -$0.32 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's EPS (Weighted Average and Diluted) are -$0.32 (Q4 2025), -$0.02 (Q3 2025), and $0.06 (Q2 2025).